Table 1.

Published series on dendritic cell-based immunotherapy in pancreatic cancer

Tumor-associated antigen	Year	Na	Stage	Pulsation	R	SD	PD	Median survival (months)
MUC1
Pecher et al. [31]	2002	2	Unresectable	cDNA		0	2
Kondo et al. [32]	2008	20	Unresectable	Peptide	1	5	14	9.8b
Lepisto et al. [33]	2008	12	Resectable	Peptide	4			26
Rong et al. [34]	2012	7	Unresectable	Peptide		0	7
Shindo et al. [35]	2014	42	Unresectable	mRNA	4	22	16	13.9
WT1
Koido et al. [37]	2014	10	Unresectable	Peptide		7	3
Takakura et al. [39], Tsukinaga et al. [40]	2015	7	Unresectable	Peptide		6	1	10.8
Mayanagi et al. [38]	2015	10	Unresectable	Peptide		6	4	8.3
Okamoto et al. [41]	2016	255	Unresectable	Peptide				9.9
Mesothelin
Thomas et al. [43]	2004	14	Unresectable	Peptide	Immunological response in 3 patients
KRAS
Gjertsen et al. [45]	1996	5	Unresectable	Peptide		3	2	5
hTERT, CEA, survivin
Mehrotra et al. [55]	2017	12	Unresectable	Peptide				7.7
CEA, HER2, WT1
Kimura et al. [56]	2012	49	Unresectable	Peptide	7	10	32	11.8
CEA, MUC1
Nakamura et al. [59]	2009	12	Unresectable	Peptide, lysate				9
Tumor cell lysate
Bauer et al. [61]	2011	12	Unresectable	Lysate	1	2	9	10.5

PD progressive disease, R partial or complete response to therapy, SD stable disease

^aOnly patients with pancreatic cancer were considered.

^bMean survival time